adjunctive-phage-therapy-achieves-eighty-two-percent-remission-in-refractory-musculoskeletal-infections
Adjunctive Phage Therapy Achieves Eighty-Two Percent Remission in Refractory Musculoskeletal Infections

Adjunctive Phage Therapy Achieves Eighty-Two Percent Remission in Refractory Musculoskeletal Infections

In a prospective clinical evaluation, personalized adjunctive bacteriophage therapy achieved clinical remission in nine of eleven evaluable patients, documenting an 82 percent remission rate among individuals suffering from difficult-to-treat musculoskeletal infections. The prospective assessment evaluated the therapeutic strategy alongside conventional surgical intervention and systemic antimicrobial treatment, targeting severe and persistent bone and joint conditions where previous therapeutic regimens had failed to achieve resolution.

Musculoskeletal infections, which include fracture-related infections and periprosthetic joint infections, remain notoriously difficult to treat in clinical settings due to biofilm formation and increasing antimicrobial resistance. Although bacteriophage therapy has re-emerged as a promising adjunctive strategy to counter recalcitrant bacterial pathogens, rigorous prospective clinical evidence demonstrating its real-world implementation and performance has remained scarce across medical literature.

To evaluate this clinical approach under prospective conditions, researchers evaluated adjunctive local bacteriophage therapy in a group of thirteen patients diagnosed with refractory musculoskeletal infections. All thirteen treated individuals received their specialized care within the multidisciplinary PHAGEFORCE framework at University Hospitals Leuven in Belgium, enabling coordinated clinical, surgical, microbiological, and genomic oversight throughout the entire therapeutic course.

To provide an observational comparison within the clinical evaluation, the study followed a control cohort consisting of four patients with refractory musculoskeletal infections who lacked suitable, matching phages for therapy. This parallel control group allowed researchers to observe patient outcomes under conventional clinical management in refractory cases where personalized bacteriophage options could not be prepared.

The standardized intervention protocol began following operative surgery, after which personalized bacteriophage preparations were administered locally through a closed drain system for eight to ten days in combination with systemic antibiotics. Throughout this therapeutic window, the multidisciplinary investigative team systematically collected comprehensive clinical, microbiological, immunological, and longitudinal genomic data to track the treatment’s safety and biological behavior.

Follow-up evaluations documented clinical remission in nine of the eleven evaluable phage-treated patients, representing an 82 percent success rate in that cohort. In contrast, all four patients in the control cohort experienced infection recurrence during their follow-up observation periods. Furthermore, the local phage regimen was well tolerated across all treated participants, with no serious adverse reactions or clinically meaningful toxicity reported.

Microbiological analyses confirmed that local phage titers remained detectable throughout the full duration of treatment, despite notable interpatient variability. Although laboratory evaluations detected serum-mediated phage neutralization during and after therapy, and longitudinal genomic monitoring revealed patient-specific phage dynamics, neither finding was clearly associated with clinical outcome. The study authors concluded that these results establish the feasibility and safety of standardized local phage therapy, providing strong support for further evaluation in controlled clinical trials.

Subject of Research: Personalized adjunctive bacteriophage therapy for refractory musculoskeletal infections

Article Title: Personalized adjunctive phage therapy for difficult-to-treat musculoskeletal infections

Article References: Bessems, L., Sykora, L., Depypere, M., Debaveye, Y., Spriet, I., Devolder, D., De Munter, P., Henckaerts, L., Vles, G., Wafa, H., Lavigne, R., Verwimp, S., Van Noort, V., Green, S., Merabishvili, M., Pirnay, J.-P., Molenberghs, G., Onsea, J., & Metsemakers, W.-J. (2026). Personalized adjunctive phage therapy for difficult-to-treat musculoskeletal infections. Nature Communications. https://doi.org/10.1038/s41467-026-79305-y

Image Credits: AI Generated

DOI: 10.1038/s41467-026-79305-y

Keywords: bacteriophage therapy, musculoskeletal infections, fracture-related infections, periprosthetic joint infections, biofilm formation, antimicrobial resistance, adjunctive therapy, PHAGEFORCE framework, University Hospitals Leuven, closed drain system, systemic antibiotics, clinical remission, local phage administration, phage neutralization, genomic monitoring, refractory infections, phage titers, controlled clinical trials